{"nctId":"NCT00594516","briefTitle":"Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain","startDateStruct":{"date":"2007-12"},"conditions":["Low Back Pain"],"count":117,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: tapentadol (CG5503) Immediate Release IR","Drug: tapentadol (CG5503) Immediate Release (IR)"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: tapentadol (CG5503) Extended Release (ER)"]}],"interventions":[{"name":"tapentadol (CG5503) Immediate Release IR","otherNames":[]},{"name":"tapentadol (CG5503) Extended Release (ER)","otherNames":[]},{"name":"tapentadol (CG5503) Immediate Release (IR)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Low Back Pain (LBP) of non-malignant origin present for at least 3 months immediately before study entry\n* Taking drug treatment for pain for at least 3 months before screening and who are dissatisfied with current therapy\n* Subjects receiving opioid treatment must have a total daily opioid dose \\<= 160 mg/day of oral morphine equivalent\n* For entry into open label period patients must have a baseline score \\>=5 on an 11-point NRS, calculated as the average pain intensity during the last 3 days of the washout period\n* For entry into the double-blind period subjects must have remained on the same optimal stable dose and frequency of tapentadol (CG5503) IR administration during the last 3 days of the open-label treatment period\n\nExclusion Criteria:\n\n* Presence of conditions other than Low Back Pain (LBP) that could make it hard to assess or self-evaluate pain\n* Surgery in low back area within 3 months of screening or expected surgery in the low back area during the study\n* Any scheduled surgery or painful procedure during the study, or any clinically significant disease that, in the opinion of the investigator, may affect efficacy or safety assessments\n* History of malignancy within the past 2 years, with the exception of basal cell carcinoma that has been treated and is no longer present\n* Women who are pregnant or breast-feeding\n* Moderately or severely impaired liver function\n* Severely impaired kidney function\n* History of chronic hepatitis B or C, or HIV, or presence of active hepatitis B or C in past 3 months\n* History of seizure disorder\n* Alcohol or drug abuse\n* Uncontrolled high blood pressure\n* Clinically relevant history of hypersensitivity, allergy, or contraindications to acetaminophen or opioid analgesics (or ingredients)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Difference in the Mean Average Pain Intensity Score on an 11-point Numerical Rating Scale (NRS) During the Last 3 Days of Each Double-blind Treatment Period. (Difference Between Two DB Randomization Treatment Sequences)","description":"For this twice daily pain assessment, the subjects were to indicate the level of average pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated \"no pain\" and a score of 10 indicated \"pain as bad as you can imagine\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients Requiring Rescue Medication During the DB Tapentadol IR Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients Requiring Rescue Medication During the DB Tapentadol ER Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Daily Dose (TDD) of Tapentadol IR During the Double-blind Treatment Period","description":"Average total daily dose (TDD) of tapentadol IR during the double blind treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"331.0","spread":"116.17"}]}]}]},{"type":"SECONDARY","title":"Total Daily Dose (TDD) of Tapentadol ER During the DB Treatment Period.","description":"Average total daily dose (TDD) of tapentadol ER during the double-blind treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"330.4","spread":"123.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":116},"commonTop":["Dizziness","Headache","Somnolence","Nausea","Fatigue"]}}}